Experienced medication helps people lose about 25% of their body weight

Experimental Weight Loss Drug It is indicated that people have helped to lose about 25% of their body weight in previous-stage 1A / 2B tests.

Peptide and powerless feeling, ozemptical and strengthening such as huncretin and grucongon, which regulate the feeling of amycretin and fullness of the appetite – the same hormone that regulates the sense of administrator and fullness of the Novo Nordisk Insulin secretion.

“Two different biological roads stimulated by Amycretin, factor and GLP-1 in a single molecule,” In Martin Holst Lange, President of the Executive President and Development Novo Nordisk, Fox News said in a statement sent to Fox News digital statement.

The simple changes of the grandfather, changed diabetes diabetes before diabetes leaving him ‘petrified’

125weight or obese adults, in the business included in the participants Weekly injections Amycretin, Novo Nordisk’dan a press release, a press release that has lost more weight.

Those with the highest doses (up to 60 mg) increased by 24.3% in 36 weeks to increase only 1.1% for the released place.

The previous step-1 test of the Verbal (pill) version of Amycret was “safe and tolerant” compared to Plasebo.

Took the pill once a day and took it around 10% weight loss lossAnd those who lost the dose twice, lost 13%.

DNA may hinder your weight loss, offers a new study

Another emphasis on the researchers, people who emphasize the Amycretin, the “Weight Loss Plateau” was shot dead.

“Lack of weight loss, weight loss indicates the possibility of decreasing the next weight extended treatment“A large clinical pharmacology specialist in Novo Nordisk Agnes Gasoirek wrote as a result of Phase 1 research.

Novo Nordisk presented the latest findings in the American Diabetes Association in Chicago on June 22; They were also published in a medical journal.

“We are pleased with the opinion of Amycretin and ceiling, and this molecule is pleased to develop 4 subcutants and verbal weight management,” Martin Holst Lange, Assistant Development Assistant Development in Novo Nordib

“Amycretin is the first treatment to use two different biological paths stimulated in a single molecule of Amylin and GLP-1.”

“These results reflect our healthy pipeline (and) to develop scientific innovation and the expansion of existing options for patients and health workers.”

Other GLP-1S similar amycreti was the most common side effects Gastrointestinal symptoms – First of all, nausea, the vomiting and appetite decreased.

Click here to get FOX News app

According to researchers, negative events were “moderately moderately” in violence. More often doses resulted in more side effects.

It is important to watch these side effects closely, experts advise because it is very common among GI problems Patients with obesity.

“Although the initial weight loss results are truly inspiring, additional studies need additional research to ensure that therapeutic benefits are superior to potential risks, especially with long-term management, director and head Bariatric Surgery The New Langone Weight Management Program said that Fox News is digital before.

Click here to sign up for our health newsletter

GLP-1-based medications – this new experimental pill, including prospective results, can show a non-participation in the character, “not a treatment for obesity,” he said.

“Obesity is a chronic, multi-terrorist disease that requires a comprehensive, long-term approach,” he said.

Visit for more health articles www.foxnews.com/setich

“Pharmacological treatment can play an important role in the management of the situation, but often they are most effective when they are combined Other interventions“

The next, Novo Nordisk, for obesity management, plans to prepare for 3 trials of medicines in both oral and injectable form.